Vir Biotechnology, Inc., a cutting-edge immunology firm, is carving out a prominent place in the medical world with its innovative therapeutic products designed to battle severe infectious conditions. Among its most notable developments is Sotrovimab (VIR-7832), which features SARS-CoV-2-neutralizing monoclonal antibodies aimed at treating and preventing COVID-19. Already available under the highly anticipated Xevudy brand, this product represents a major step forward in the fight against the pandemic. Vir Biotechnology is also working on VIR-2218 and VIR-3434 treatments for the hepatitis B virus, VIR-2482 to prevent influenza A virus, and VIR-1111 for stopping the human immunodeficiency virus before it can take hold. The firm enjoys a wealth of partnerships and agreements, including collaborations with WuXi Biologics, Glaxo Wellcome UK Ltd., and Gilead Sciences, Inc. Notably, it has also secured funding from Bill & Melinda Gates Foundation and National Institutes of Health. Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology is making strides on multiple fronts to address critical medical needs.
Vir Biotechnology, Inc.'s ticker is VIR
The company's shares trade on the NASDAQ stock exchange
They are based in San Francisco, California
There are 201-500 employees working at Vir Biotechnology, Inc.
It is https://www.vir.bio/
Vir Biotechnology, Inc. is in the Healthcare sector
Vir Biotechnology, Inc. is in the Biotechnology industry
The following five companies are Vir Biotechnology, Inc.'s industry peers: